GAITHERSBURG, Md., March 22, 2022 /PRNewswire/ MaxCyte, Inc., (NASDAQ: MXCT) (LSE: MXCT) is a leading commercial cell-engineering company focused on providing enabling platform technologies
Share this article
Share this article
GAITHERSBURG, Md., July 12, 2021 /PRNewswire/ MaxCyte, Inc., (LSE: MXCT) (LSE: MXCN), a leading provider of platform technologies for cell engineering (
MaxCyte or the
Company ), today announced the public filing of a registration statement on Form S-1 with the Securities and Exchange Commission (the SEC ) for a proposed dual-listing and public offering of shares of common stock on the Nasdaq Stock Market (the offering ). The registration statement included a proposed change to the board of directors as well as unaudited financial information which is detailed below.
Financial information in the Form S-1 registration statement
The Company s Form S-1 registration statement contains unaudited consolidated financial statements for the period from 1 January 2021 to 31 March 2021 prepared in accordance with generally accepted accounting principles in the United States ( U.S. GAAP ). Such consolidated financial statements, as extracted
Myeloid Therapeutics Launches with Over $50 Million in Financing and Two Clinical Trials
Myeloid s cell therapy harnesses the innate capabilities of myeloid lineage cells to fight cancer
Scientific founders include world-renowned cell therapy & cancer experts Ronald Vale, Ph.D. and Siddhartha Mukherjee, M.D., D.Phil.
Co-Founded by Thomas Cahill, M.D., Ph.D., with financing led by Newpath Partners and participation from leading biotech investors
News provided by
Share this article
Share this article
CAMBRIDGE, Mass., Jan. 6, 2021 /PRNewswire/ Myeloid Therapeutics, Inc., a company harnessing and reprogramming myeloid cells for treating cancers, launched today with over $50 million in financing to initiate multiple clinical trials in 2021. The Company combines advanced gene and cell engineering capabilities with substantial biologics knowledge to elucidate and redirect the power of myeloid cells to treat cancers, particularly solid tumors and those that are poorly served by exi